Abstract

Therapeutic Considerations of Mesenchymal Stromal Cells

Ling-Mei Wang, President and COO, Steminent Biotherapeutics

Mesenchymal Stromal Cells (MSCs), with its unique anti-inflammatory and immunomodulatory functions, have been widely considered as a viable drug agent for many unmet or underserved disease indications. Anyhow challenges remain before we can see more popularized clinical applications. Some critical dimensions include the high level of biological complexities, regulatory requirements, and manufacturing scale-up. This presentation will have an overview of some essential issues to be considered, along with suggested approaches in developing viable clinical use of MSCs. Steminent Biotherapeutics, with its proprietary allogenic stem cell technologies, will present some of the key findings of utilizing MSC-based treatments on Spinocerebellar Ataxia (SCA) and Acute Liver Failures (ALF), both are debilitating medical needs without effective options.